Category: <span>clinical trial</span>

Immunotherapy Trial for Mesothelioma Shows Early Promise

The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…

The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.